'Vouching' for Regeneron in PCSK9 market race: Amgen catch-up via coupon buy from Biomarin?
In the race with Amgen Inc. to market a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for high cholesterol, Regeneron Pharmaceuticals Inc. played catch-up by buying a priority review voucher (PRV) for $67.5 million from Biomarin Pharmaceutical Inc., splitting the cost with alirocumab partner Sanofi SA.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST